Brukinsa (zanubrutinib) — United Healthcare

Initial criteria

• Diagnosis of hairy cell leukemia AND Disease is relapsed, refractory, or progressive

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Brukinsa therapy

Approval duration

12 months